Capivasertib plus fulvestrant in patients with AI-resistant, HR-positive, HER2-negative advanced breast cancer: Exploratory analyses of PTEN deficiency in CAPItello-291

Breast Cancer

Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial

Lancet Oncol

Oliveira M, Rugo HS, Howell SJ, Dalenc F, Cortes J, Gomez HL, Hu X, Toi M, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Nowecki Z, Park YH, Sohn JH, Tokunaga E, Yousef S, Zhukova L, Fulford M, Andrews H, Wadsworth I, D'Cruz C, Turner NC, CAPItello-291 study group

doi: 10.1016/S1470-2045(24)00373-5

SABCS 2024

Breast Cancer

CAPItello-291: Comparable prevalence of PIK3CA/AKT1/PTEN alterations in primary and recurrent tumors in HR-positive, HER2-negative breast cancer

ASCO 2024

Breast Cancer

NATALEE: Ribociclib plus NSAI is effective and tolerable in patients with high-risk node-negative HR-positive, HER2-negative early breast cancer

ESMO 2024

Breast Cancer

ABIGAIL: Abemaciclib plus endocrine therapy improves ORR versus paclitaxel in patients with advanced HR+/HER2- breast cancer with aggressive disease criteria

SABCS 2024

Breast Cancer

EMBER-3: Imlunestrant significantly improves PFS in patients with ER-positive, HER2-negative advanced breast cancer with ESR1 mutations

ASCO 2024

Breast Cancer

monarchE: ctDNA detection is highly prognostic of worse clinical outcomes in patients with HR-positive, HER2-negative, lymph node-positive early breast cancer

SABCS 2024

Breast Cancer

SERENA-1: Camizestrant plus ribociclib show encouraging clinical activity in women with ER-positive, HER2-negative advanced breast cancer

SABCS 2024

Breast Cancer

PADMA: First-line palbociclib plus ET improves TFF and PFS versus chemotherapy in patients with high-risk HR-positive/HER2-negative metastatic breast cancer

ASCO 2024

Breast Cancer

Related content

Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial

CAPItello-291: Comparable prevalence of PIK3CA/AKT1/PTEN alterations in primary and recurrent tumors in HR-positive, HER2-negative breast cancer

NATALEE: Ribociclib plus NSAI is effective and tolerable in patients with high-risk node-negative HR-positive, HER2-negative early breast cancer

ABIGAIL: Abemaciclib plus endocrine therapy improves ORR versus paclitaxel in patients with advanced HR+/HER2- breast cancer with aggressive disease criteria

EMBER-3: Imlunestrant significantly improves PFS in patients with ER-positive, HER2-negative advanced breast cancer with ESR1 mutations

monarchE: ctDNA detection is highly prognostic of worse clinical outcomes in patients with HR-positive, HER2-negative, lymph node-positive early breast cancer

SERENA-1: Camizestrant plus ribociclib show encouraging clinical activity in women with ER-positive, HER2-negative advanced breast cancer

PADMA: First-line palbociclib plus ET improves TFF and PFS versus chemotherapy in patients with high-risk HR-positive/HER2-negative metastatic breast cancer

SACI-IO HR+: Adding pembrolizumab to sacituzumab govitecan shows numerical PFS improvement in HR-positive, HER2-negative breast cancer